PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This program offers a personalized vaccine called PCNAT-01 to patients with pancreatic cancer who have had surgery and finished chemotherapy. The vaccine is made from each patient's unique tumor proteins and is given as shots to train the immune system to fight any remaining canc…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…

This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This study tests a new drug called BNT327 combined with standard chemotherapy in adults with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination shrinks tumors better than chemo alone. About 105 participants will be enrolled, and r…

This early-phase trial is testing whether adding the drug fostamatinib to standard chemotherapy can help people with resectable pancreatic cancer. Fostamatinib is already approved for a blood disorder but has not been tried in pancreatic cancer. The study will enroll 36 participa…

This early-stage trial tests a new type of immunotherapy for people with advanced pancreatic cancer that has spread or cannot be removed. The treatment uses specially engineered natural killer (NK) cells that target two cancer-related proteins at once. Up to 42 participants will …

This study tests a new oral drug called JYP0015 in people with advanced solid tumors (such as pancreatic, lung, or colorectal cancer) that have a RAS mutation. The drug aims to block the activity of the mutated RAS protein, which drives cancer growth. The trial will enroll 210 pa…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This early study tests a new device called YntraDose™ that delivers a single dose of radiation directly into pancreatic tumors that cannot be removed by surgery. Ten participants will receive the implant along with standard chemotherapy. The main goals are to see if the procedure…

This early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard IV chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will receiv…

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…

This Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This early-stage trial tests a new drug called ProAgio combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer that has spread. Some participants also get an immunotherapy drug (atezolizumab). The main goals are to find a saf…

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …

This study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…

This study tests a new type of PET scan that uses a tracer called FAPI to see if it can find pancreatic cancer progression or relapse earlier than standard CT or MRI scans. 35 adults with non-spread pancreatic cancer will receive the FAPI-PET scan at several points during their t…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study tests a special medical food powder (Encala®) in 18 adults with pancreatic cancer who have trouble absorbing fat, causing stomach issues and weight loss. The goal is to see if the powder is easy to take and helps improve fat absorption and quality of life. This is an e…

This study aims to understand why liver metastases are so deadly in colorectal and pancreatic cancers. Researchers will analyze tumors and blood from 625 participants to find new targets for immune and gene therapies. The goal is to develop better treatments for these hard-to-tre…